Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy (Q43030920)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2006

Language	Label	Description	Also known as
English	Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy	scientific article published in September 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

Ming-Lung Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wan-Long Chuang

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Chia-Yen Dai

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Li-Po Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ming-Yen Hsieh

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Zu-Yau Lin

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shinn-Cherng Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ming-Yuh Hsieh

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liang-Yen Wang

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wen-Yu Chang

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sun-Lung Tsai

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hsing-Tao Kuo

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Translational Research

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

148

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

120-127

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

How can mathematics help us understand HCV?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Treatment of chronic hepatitis C in southern Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Racial differences in HLA class II associations with hepatitis C virus outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.04.006

7 January 2021

Identifiers

10.1016/J.TRSL.2006.04.006

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43030920&oldid=1977642112"